People Round-Up: Glenmark Recruits API Head From Mylan

Glenmark chooses a head for its API unit, Lannett’s CFO retires, and Sterling Pharma Solutions names a leader in the US.

People
• Source: Shutterstock

Glenmark Pharmaceuticals has appointed Yasir Rawjee as CEO of its active pharmaceutical ingredient subsidiary Glenmark Life Sciences. He joins the Indian firm from Mylan, where he was most recently head of global API operations, having held positions of increasing responsibility in the firm’s API business during his career there. Rawjee has also served at GlaxoSmithKline and Matrix Laboratories, which was acquired by Mylan. Glenmark’s chairman and managing director, Glenn Saldanha, said the firm saw “significant growth potential in our API business given the increasing demand for good quality and sustained supply of APIs globally”, noting that “with this view, we housed our API business into a separate subsidiary which will be run independently.” Rawjee pledged to “contribute meaningfully in scaling up and shaping the next leg of growth for the API unit.”

Lannett’s chief financial officer, Martin Galvan, has announced plans to retire on 30 August 2019, following the submission of...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Leadership

Kris Joshi Named Norstella CEO, Prioritizes AI Innovation

 
• By 

Joshi joins the parent company of Citeline, which houses flagship publications Generics Bulletin, Scrip and Pink Sheet, to focus on AI, business harmonization and long-term growth.

Who’s Hired? Stada Picks Biogen’s Biosimilars Chief Henshaw To Lead Specialty Segment

 
• By 

Stada has appointed former Biogen biosimilars head Ian Henshaw as the new leader of its Specialty segment. Meanwhile, Craig Burton has left the AAM for Fresenius Kabi, Australia's GBMA is looking for a new chief executive, and Speranza, Outlook and EuroAPI have announced new appointments.

Bridging The Void: How Biocon Biologics Sees The Future Of Biosimilars In Europe

 
• By 

As Biocon Biologics picks up the latest approvals in Europe for its Stelara biosimilar, Blake Leitch, the firm’s head of Europe, talks to Generics Bulletin about what lies ahead for Biocon and for biosimilars more widely in the region – including tackling the “biosimilar void”.

Finding The Right Leadership In A Fast-Moving Industry: Parsity Group’s Nathan Talks Recruitment

 
• By 

What makes the generics and biosimilars sector unique when it comes to executive talent searches and recruitment? Dan Nathan, founder and managing director of Parsity Group, talks to Generics Bulletin about how the firm operates in the fast-moving global off-patent industry.

More from Generics Bulletin

MSN Labs Swerves 2026 US Entresto Patent Ahead Of Separate July 15 Expiry

 
• By 

Novartis has filed an immediate appeal after a US district court ruled that MSN Labs would not infringe one of its key patents shielding its $7.8bn Entresto brand, and denied the originator injunctive relief.

UK Sitagliptin Prices Shoot Up In June

 
• By 

Multiple strengths of sitagliptin saw average price increases that topped our rundown of UK generic pricing data in June.

Biocon’s Denosumab Biosimilar Approved In The UK As Competition Grows In Europe

 

Denosumab biosimilar ranks are filling up in Europe as approvals flood in. Yet, little is known about the launch dates.